Acepodia, Inc. Stock

6976

KYG0073G1091

Biotechnology & Medical Research

End-of-day quote Taipei Exchange Other stock markets 2026-07-29			5-day change	1st Jan Change
11.95 ^TWD	-3.63%		-8.43%	-22.15%

03-25	Acepodia, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
01-09	Biocytogen Pharmaceuticals Co., Ltd. and AcePodia Expand Collaboration Through Option-Based Evaluation Framework for First-In-Class Bispecific and Dual-Payload ADCs	CI

Acepodia Inc is engaged in the research and development of new anti-cancer drugs. The Company uses antibody-cell conjugation (ACC) and immune cells. The products include Gamma delta 2T cell platform including ACE1831 (ACE-gdT-CD20) an antibody linked to specific target CD20 for treatment of lymphoma, ACE2016 (ACE-gdT-EGFR) an antibody linked to specific target EGFR , the target treatment of EGFR+ solid tumors, such as lung cancer, ACE1708 (ACE-gdT-PDL1) an antibody linked to the specific target PDL1 antibody, the target treatment of solid tumors; off-the-shelf natural killer (oNK) cell platform including ACE1702 (ACE-oNK-HER2) linked to a specific target HER2 antibody, targeting treatment of HER2+ solid tumors, such as breast cancer. The technologies include antibody cell linking technology, Gamma delta 2T cell screening, culture and amplification technology, oNK cell culture and amplification technology, Acepodia series of new cell drug preparations freezing and thawing technology.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-07-29	NT$11.95	-3.63%	688,385
26-07-28	NT$12.40	-0.40%	412,163
26-07-27	NT$12.45	-3.11%	97,611
26-07-24	NT$12.85	+1.18%	529,356
26-07-23	NT$12.70	-0.78%	639,655

End-of-day quote Taipei Exchange

More quotes

Income Statement and Estimates

More financial data

Stock Market
Stocks
6976 Stock

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	6.97B 215M 187M 175M 161M 302M 20.59B 310M 2.07B 810M 10.21B 808M 791M 35.17B	P/E 2024	-20x	P/E 2025	-11.8x
Enterprise Value	3.42B 106M 92.15M 86M 79.04M 148M 10.12B 152M 1.02B 398M 5.02B 397M 389M 17.29B	EV / Sales 2024	9,735,924,522x	EV / Sales 2025	29,160,315,200x
Free-Float	100%	Yield 2024 *	-	Yield 2025	-

03-25	Acepodia, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
01-09	Biocytogen Pharmaceuticals Co., Ltd. and AcePodia Expand Collaboration Through Option-Based Evaluation Framework for First-In-Class Bispecific and Dual-Payload ADCs	CI
25-08-13	Acepodia, Inc. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-05-28	Acepodia and Pfizer To Terminate Cooperation in Autoimmune Diseases Drugs Development	RE
25-05-28	AcePodia, Inc. Provides Update on Collaboration Under the Pfizer Ignite Program	CI
25-05-28	Acepodia, Inc. Announces CFO Changes, Effective from May 28, 2025	CI
25-05-28	Taiyo Yuden Co., Ltd. Announces Executive Changes, Effective from May 28, 2025	CI
25-03-19	Acepodia, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-02-17	AcePodia Biotech, Inc. Announces Clearance of the IND by the Taiwan Food and Drug Administration for Investigational Product ACE2016	CI
25-01-07	Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors	CI
24-12-13	Acepodia Biotech, Inc. Announces Clearance of the IND by the U.S. FDA for Investigational Product ACE1831	CI
24-12-11	Acepodia, Inc. Announces Board Changes	CI
24-12-11	Acepodia, Inc. Announces Retirement of Patrick Yuhmin Yang as Chief Strategy Officer, Effective December 31, 2024	CI

1 day	-3.63%
1 week	-8.43%
Current month	-10.15%
1 month	-8.43%
3 months	-3.24%
6 months	-16.14%
Current year	-22.15%

1 week	11.75	12.85
1 month	11.75	13.6
Current year	10.85	15.75
1 year	10.85	19.15
3 years	10.85	65
5 years	10.85	65
10 years	10.85	65

Manager	Title	Age	Since
Sonny Hsiao CEO	Chief Executive Officer	-	2017-02-14
Yan Ta Lai DFI	Director of Finance/CFO	-	2017-03-31
Lapyuen Lam CTO	Chief Tech/Sci/R&D Officer	68	2022-03-31

Acepodia, Inc. Stock

Stocks

6976

KYG0073G1091

Biotechnology & Medical Research

Valuation: Acepodia, Inc.

Chart: Acepodia, Inc.

Latest news : Acepodia, Inc.

Press Releases: Acepodia, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Acepodia, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Director	Title	Age	Since
Patrick Yang CHM	Chairman	78	2017-02-14
Sonny Hsiao BRD	Director/Board Member	-	2017-02-14
Samuel Chen BRD	Director/Board Member	75	2021-10-13

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ACEPODIA, INC.	-3.63%	-8.43%	-22.65%	-	223M
LONZA GROUP AG	+2.61%	+1.91%	+1.70%	+13.91%	47.88B
REVOLUTION MEDICINES, INC.	-1.60%	-1.29%	+385.56%	+603.70%	39.09B
BEONE MEDICINES AG	-0.98%	+2.68%	+11.10%	+45.34%	36.75B
IQVIA HOLDINGS INC.	+1.90%	+22.79%	+25.18%	+9.47%	40.55B
CELLTRION, INC.	+1.47%	+4.90%	+6.48%	+43.52%	27.96B
ASCENDIS PHARMA A/S	-0.94%	-1.23%	-	-	16.77B
MEDPACE HOLDINGS, INC.	+2.44%	+10.02%	+29.11%	+129.56%	15.94B
EUROFINS SCIENTIFIC SE	+0.18%	-1.46%	+4.92%	+10.14%	13.55B
ICON PUBLIC LIMITED COMPANY	-1.14%	+6.94%	-6.05%	-29.33%	13.81B
Average	+0.03%	+3.61%	+48.37%	+103.29%	25.25B
Weighted average by Cap.	+0.61%	+5.05%	+72.98%	+124.52%

	2024	2025
Net sales	0.43 0.01 0.01 0.01 0.01 0.02 1.26 0.02 0.13 0.05 0.63 0.05 0.05 2.16	0.18 0.01 0 0 0 0.01 0.55 0.01 0.06 0.02 0.27 0.02 0.02 0.93
Net income	-497M -15.35M -13.37M -12.48M -11.47M -21.53M -1.47B -22.08M -148M -57.77M -728M -57.64M -56.38M -2.51B	-754M -23.32M -20.3M -18.95M -17.42M -32.7M -2.23B -33.53M -225M -87.74M -1.11B -87.53M -85.63M -3.81B
Net Debt	-5.82B -180M -157M -146M -134M -252M -17.2B -259M -1.73B -677M -8.53B -675M -661M -29.38B	-3.54B -109M -95.31M -88.95M -81.75M -153M -10.47B -157M -1.05B -412M -5.19B -411M -402M -17.88B